Live feed06:30:00·1482dPRReleasevia QuantisnowVeru's Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming EfficacyByQuantisnow·Wall Street's wire, on your screen.VERU· Veru Inc.Health Care
